Removable stent and method of using the same

Abstract
The present invention, in an exemplary embodiment, provides a stent, which combines many of the excellent characteristics of both silicone and metal stents while eliminating the undesirable ones. In particular, it is an objective of a preferred embodiment of the present invention to provide a stent that is easily installed, yet removable. Moreover, the stent does not cause material infections and has the capacity to reduce infection. Therefore, a principal objective of a preferred embodiment in accordance with the present invention is to provide a prosthesis that is suitable for both permanent and temporary use while being easy to insert, reposition and remove. This prosthesis is also suitable for targeted delivery of antimicrobial and chemotherapeutic agents. Additionally, a principal objective in accordance with the present invention is to provide a family of stents where the relative hardness/softness of regions of the stent can differ from other regions of the stent to provide additional patient comfort and resistance to radial forces. An exemplary embodiment also provides a family of stents with novel interstice configurations that facilitate flexibility, durability and/or proper installation.
Description
FIELD OF THE INVENTION

The present invention relates generally to medical devices directed to the prevention of nonvascular vessel or passageway occlusion, and more particularly to removable tracheal/bronchial stents and methods for utilizing these stents in the treatment of both benign and malignant conditions.


BACKGROUND OF THE INVENTION

Stents are devices that are inserted into a vessel or passage to keep the lumen open and prevent closure due to a stricture, external compression, or internal obstruction. In particular, stents are commonly used to keep blood vessels open in the coronary arteries and they are frequently inserted into the ureters to maintain drainage from the kidneys, the bile duct for pancreatic cancer or cholangiocarcinoma or the esophagus for strictures or cancer.


In particular, airway stents are principally utilized for four indications, namely: (1) re-establishment of airway patency due to extrinsic tracheobronchial compression from either mass or lymph nodes; (2) re-establishment of airway patency due to intrinsic tracheobronchial obstruction from malignant or benign disease; (3) to cover a fistula track secondary to tracheo-esophageal fistula; and/or (4) to maintain airway patency in patients with tracheobronchial malacia. There are currently two basic types of stents available for some but not all of these indications: polymer or metal.


In 1990 a silicone stent developed by Dumon was reported upon in the medical literature, it is currently the most widely utilized stent in the world. The primary advantage of the silicone stent is its removability. However, this stent must be placed through a rigid metal tube (rigid bronchoscopy), in an operating suite, under general anesthesia, which increases the cost of the procedure and potentially places the patient at greater risk for complications. This technique requires extensive training and is only performed at specialized centers. The Dumon stent is thick-walled, which increases airway resistance and decreases mucociliary clearance. This problem leads to mucous impaction and tracheobronchitis. Additionally, these polymer stents are of fixed luminal diameter and do not self expand to meet the changing contour of the airway. This leads to a problem with stent migration. The cylindrical tube design does not conform to curved or conical airway anatomy and they also cause the formation of granulation tissue, which results from airway irritation.


In light of these disadvantages, and at the expense of removability, industry has moved away from the polymer stent in favor of the self-expanding metal stent. The two most widely used are the ultraflex and wall stent, which have shape memory characteristics. They are self-expanding and can be placed through a flexible bronchoscope, under conscious sedation, using local anesthesia in an outpatient setting. They have sufficient wall to lumen ratio, minimal interference with mucociliary clearance and conform to difficult airway anatomy. Unfortunately, after approximately six weeks, the wire mesh in these stents becomes epithelialized, thus making removal difficult, if not impossible.


Rejection of the stent can occur with severe airway irritation and tracheobronchitis that is impossible to treat because the nidus for the infection is the metal, which cannot be removed. Because of the inability to remove these stents, they are indicated only as a last resort for benign disease. Additionally, these stents can be challenging to deploy because they can elongate or foreshorten, depending upon the diameter of the airway.


An additional disadvantage of conventional metal stents is that they can migrate, like polymer stents, since the axial working length of these stents varies when the stent is radially compressed. Attempts have been made to address this problem by providing a stent that is comprised of knit layers of metal to form a wire mesh with peristaltic capabilities. Unfortunately, by preparing a stent from twisted wire portions, the likelihood of tissue aggravation increases because the weaved loops of the stent dislocate when subjected to radial compression. Moreover, for certain stents, sharp edges exist at the final loop ends.


As a result, physicians have the intractable dilemma of having to decide whether the patient should undergo the intricate procedure to receive the removable polymer stent, which can migrate and/or cause granulation tissue formation, and is subject to recurrent infections. Though the metal stent is easier to implant, the risk of infection and granulation tissue formation is not reduced because the stents become epithelialized and, therefore, impossible to remove.


An additional limitation of conventional stents is the inability to adapt a single design to diverse locations of the patient's anatomy. For example, as a result of differences in topology, physicians are generally required to find different devices from different manufacturers to address conditions in varying parts of the patient's anatomy. A uniform design and method of implantation while still allowing for the shape and resiliency modification necessary to accommodate the intricacies of various lumens throughout the body would be advantageous. Therefore, there is a need for a uniform prosthesis or family of related devices that can address various anatomical challenges while allowing the physician to develop a comfort level with a particular product design and implantation method.


Therefore, there also remains an existing need for a prosthesis that is; removable, prevents epithelialization thereof, does not migrate, and is suitably configured to minimize infections and airway irritation. This is of principal importance because in tracheobronchial stenting, unlike other lumens in the body, the airway is constantly exposed to inhaled bacteria thus increasing the risk of infection. However, there is a need for a prosthesis that carries the above advantages while being suitable for use in a wide variety of anatomic locations within a patient. The configuration must also facilitate a method of introduction that prevents the premature elongation and foreshortening of the stent while suitably engaging the desired implantation location. The stent must also retain its axial length while undergoing radial compression. Moreover, there is an existing need for a stent that has both antimicrobial and chemotherapeutic properties so that the stent can be indicated as an early stage therapy.


There is an existing need for a prosthesis that is designed to accommodate varying tissue types in lumens of the body. In particular, there is a need for a family of stents where the relative hardness/softness of regions of the stent can differ from other regions of the stent to provide additional patient comfort and resistance to radial forces. There is also an existing need for a family of stents with novel interstice configurations that facilitate flexibility, durability and/or proper installation. Presently, there is a need for a self-expanding stent have the above benefits that also defines a plurality of apertures at the termini of the stent for, inter alia, removal of the stent.


SUMMARY OF EXEMPLARY EMBODIMENTS

It is a principal purpose of the present invention to provide a stent, in accordance with an exemplary embodiment of the present invention, which combines many of the excellent characteristics of both silicone and metal stents while eliminating the undesirable ones. In particular, it is an objective of a preferred embodiment in accordance with the present invention to provide a stent that is easily installed, yet removable. Moreover the stent in accordance with this embodiment of the present invention would not cause material infections and may be capable of reducing infection. Therefore, a principal objective of a preferred embodiment in accordance with the present invention is to provide a prosthesis that is suitable for both permanent and temporary use while being easy to insert, reposition and remove.


Another principal objective in accordance with a preferred embodiment of the present invention is to provide a tracheal/bronchial stent that is a hybrid of the metal and elastic stents, which offers optimal characteristics for the management of diseased airways. In the furtherance of this and other objectives, a stent is provided that has a shape-memory frame that is sufficiently covered with a thin coating so as to prevent epithelialization.


An additional objective of an exemplary device in accordance with the present invention is to provide a prosthesis that is suitable for use in other anatomical locations within a patient such as, by way of example only and not to be construed as limiting, the colon, the billiary tract, the urinary tract, etc., without departing from the basic product design and method manufacture and implantation contemplated by the present invention.


A principal objective of a preferred embodiment of the present invention is to provide a stent that may be stamped from preferably a single material that is capable of maintaining its axial working length when radially compressed. To this end, the stent does not have a seam that could aggravate luminal tissue.


It is yet another objective of an exemplary embodiment of the present invention to provide a stent that can be indicated for the treatment of benign and malignant disease and improve the way clinicians treat malignant airway obstruction.


Still another objective of the present invention is to provide a stent and method for installing the stent that is economical and suitable for routine purposes. In the furtherance of this and other objectives, the stent will be self-expanding and have the ability to be placed through a flexible bronchoscope under local anesthesia in the outpatient setting. Moreover, the stent will have minimal migration, cause minimal tissue granulation, will not foreshorten after deployment and mucociliary clearance will not be problematic.


Yet another objective of an exemplary embodiment in accordance with the present invention is to provide a prosthesis that will have superior internal to external diameter ratio, superior radial force with dynamic expansion, while being suitable for use in pediatric and adult patients with malignant and benign disease.


An additional objective in accordance with an exemplary embodiment of the present invention is to provide a removable self-expanding stent, formed of shape-memory material, which has the ability to be integrated with an antimicrobial agent thus dramatically reducing the incidence of infection. In the furtherance of this and other objectives, the antimicrobial agent can be coupled with the shape-memory material and/or the polymeric anti-epithilializing material that is associated with the shape-memory material.


Another objective in accordance with a preferred embodiment of the present invention is to provide a method of use, method of manufacture and a stent appropriately configured to serve as a targeted delivery device for chemotherapeutic agents so as to deliver the chemotherapeutic agent to sites of choice so as to provide the chemotherapeutic activity, prevent occlusion or both.


A principal objective of an exemplary stent in accordance with the present invention is to provide a family of stents where the relative hardness/softness of regions of the stent can differ from other regions of the stent to provide additional patient comfort and resistance to radial forces.


An additional objective in accordance with an exemplary embodiment is to provide a family of stents with novel interstice configurations that facilitate flexibility, durability and/or proper installation.


Still another objective of a preferred embodiment of the present invention is to provide a self-expanding stent have the above benefits that also defines a plurality of apertures at the termini of the stent for, inter alia, removal of the stent.


Yet another objective in accordance with an exemplary embodiment is to provide a coated stent. In the furtherance of this and other objectives, an exemplary coated still has a coating that is preferably anchored with the stent about the proximal and distal ends and is free floating there between. Moreover, the coating allows for full and independent self-expansion even after being constrained and sterilized on the delivery system. It is an additional characteristic of this objective to provide a coating that does not have to be porous but must be sufficiently durable to remain functional when the stent is flexed, recaptured or deployed.


An additional objective in accordance with a preferred embodiment of the present invention is to provide an uncovered stent that is easily removable and prevents epithelialization. In the furtherance of this and other objectives, the stent is preferably electropolished.


Further objectives, features and advantages of the invention will be apparent from the following detailed description taken in conjunction with the accompanying drawings.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 shows an elevated side perspective view of an exemplary luminal stent in accordance with the present invention.



FIG. 2 shows a side perspective view of the luminal stent shown in FIG. 1.



FIG. 3 shows an aerial perspective view of interior of the luminal stent shown in FIG. 1.



FIG. 4 shows an elevated side perspective view alternative embodiment of a luminal stent in accordance with the present invention.



FIG. 5 shows a side perspective view of an alternative embodiment of an exemplary luminal stent in accordance with the present invention.



FIG. 6 shows an elevated perspective view of an alternative embodiment of an exemplary luminal stent in accordance with the present invention.



FIG. 7 shows an aerial perspective view through the interior of the luminal stent shown in FIG. 6.



FIG. 8 shows a side perspective view of the luminal stent shown in FIG. 6.



FIG. 9 shows a perspective view showing the longitudinal expanse of the D-shaped configuration of a tracheal appliance in accordance with the present invention.



FIG. 10 shows an end view of an exemplary D-shaped tracheal appliance, in accordance with the present invention, showing the external shape of the appliance.



FIG. 11 shows an end view of an exemplary D-shaped tracheal appliance, in accordance with the present invention, looking down the lumen between the distal and proximal ends thereof.



FIG. 12 shows an aerial perspective view of the top surface of the D-shaped tracheal appliance shown in FIG. 9.



FIG. 13 shows a side perspective view of an exemplary embodiment of a medical appliance, in accordance with the invention shown in FIG. 9, wherein the D-shaped appliance is resting on its substantially flat surface.



FIG. 14 shows a magnified view of the scaffolding and interstice topology of the medical appliance shown in FIG. 1.



FIG. 15 shows a magnified portion of the scaffolding and interstice topology of the medical appliance of FIG. 1, showing how modifications in geometric dimensions affect functionality.



FIG. 16 shows an elevated side perspective view of an exemplary Y-stent luminal stent in accordance with the present invention.





DETAILED DESCRIPTION OF AN EMBODIMENT

A preferred embodiment of the stent, in accordance with the present invention, provides a removable stent that prevents epithelialization of the stent and is suitably configured to minimize infections and airway irritation. The exemplary stent is not subject to premature elongation and foreshortening but is capable of engaging the desire implantation location. The stent also retains its axial length while undergoing radial compression. Additionally, the stent has both antimicrobial and/or chemotherapeutic properties so that the stent can be indicated as an early stage therapy.


The term “antimicrobial agent” as used in the present invention means antibiotics, antiseptics, disinfectants and other synthetic moieties, and combinations thereof, that are soluble in organic solvents such as alcohols, ketones, ethers, aldehydes, acetonitrile, acetic acid, formic acid, methylene chloride and chloroform. Classes of antibiotics that can possibly be used include tetracyclines (i.e. minocycline), rifamycins (i.e. rifampin), macrolides (i.e. erythromycin), penicillins (i.e. nafcillin), cephalosporins (i.e. cefazolin), other beta-lactam antibiotics (i.e. imipenem, aztreonam), aminoglycosides (i.e. gentamicin), chloramphenicol, sulfonamides (i.e. sulfamethoxazole), glycopeptides (i.e. vancomycin), quinolones (i.e. ciprofloxacin), fusidic acid, trimethoprim, metronidazole, clindamycin, mupirocin, polyenes (i.e. amphotericin B), azoles (i.e. fluconazole) and beta-lactam inhibitors (i.e. sulbactam).


Examples of specific antibiotics that can be used include minocycline, rifampin, erythromycin, nafcillin, cefazolin, imipenem, aztreonam, gentamicin, sulfamethoxazole, vancomycin, ciprofloxacin, trimethoprim, metronidazole, clindamycin, teicoplanin, mupirocin, azithromycin, clarithromycin, ofloxacin, lomefloxacin, norfloxacin, nalidixic acid, sparfloxacin, pefloxacin, amifloxacin, enoxacin, fleroxacin, temafloxacin, tosufloxacin, clinafloxacin, sulbactam, clavulanic acid, amphotericin B, fluconazole, itraconazole, ketoconazole, and nystatin. Other examples of antibiotics, such as those listed in U.S. Pat. No. 4,642,104, herein incorporated by reference, will readily suggest themselves to those of ordinary skill in the art.


Examples of antiseptics and disinfectants are thymol, a-terpineol, methylisothiazolone, cetylpyridinium, chloroxylenol, hexachlorophene, cationic biguanides (i.e. chlorhexidine, cyclohexidine), methylene chloride, iodine and iodophores (i.e. povidone-iodine), triclosan, furan medical preparations (i.e. nitrofurantoin, nitrofurazone), methenamine, aldehydes (glutaraldehyde, formaldehyde) and alcohols. Other examples of antiseptics and disinfectants will readily suggest themselves to those of ordinary skill in the art.


It must also be kept in mind that, though not equivalent, a stent in accordance with the present invention may be prepared with antimicrobial agents in other ways customary in the art. For example, the stent may be made in its entirety or in part of an antimicrobial metal, or at least one surface of the stent may have embedded, by ion beam assisted deposition, therein with atoms of an antimicrobial metal. The antimicrobial metal may include Group II metals. Other suitable examples can be found in the art, for example U.S. Pat. No. 5,520,664, which is incorporated herein by reference. Moreover, chemotherapeutic agents can be coupled with an exemplary stent of the present invention in a manner analogous to that of antimicrobial agents.


Exemplary chemotherapeutic agents include but are not limited to cis-platinum, paclitaxol, 5-flourouracial, gemcytobine and navelbine. The chemotherapeutic agents are generally grouped as DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents, Hormonal agents and others such as Asparaginase or Hydroxyurea. Each of the groups of chemotherapeutic agents can be further divided by type of activity or compound. The chemotherapeutic agents used in combination with the anti-cancer agents or benzimidazoles of this invention include members of all of these groups. For a detailed discussion of the chemotherapeutic agents and their method of administration, see Dorr, et al, Cancer Chemotherapy Handbook, 2d edition, pages 15-34, Appleton & Lange (Connecticut, 1994) herein incorporated by this reference.


DNA-interactive Agents include the alkylating agents, e.g. Cisplatin, Cyclophosphamide, Altretamine; the DNA strand-breakage agents, such as Bleomycin; the intercalating topoisomerase II inhibitors, e.g., Dactinomycin and Doxorubicin); the nonintercalating topoisomerase II inhibitors such as, Etoposide and Teniposide; and the DNA minor groove binder Plcamydin. The alkylating agents form covalent chemical adducts with cellular DNA, RNA, and protein molecules and with smaller amino acids, glutathione and similar chemicals. Generally, these alkylating agents react with a nucleophilic atom in a cellular constituent, such as an amino, carboxyl, phosphate, or sulfhydryl group in nucleic acids, proteins, amino acids, or glutathione. The mechanism and the role of these alkylating agents in cancer therapy are not well understood. Typical alkylating agents include: Nitrogen mustards, such as Chlorambucil, Cyclophosphamide, Isofamide, Mechlorethamine, Melphalan, Uracil mustard; aziridines such as Thiotepa; methanesulfonate esters such as Busulfan; nitroso ureas, such as Cannustine, Lomustine, Streptozocin; platinum complexes, such as Cisplatin, Carboplatin; bioreductive alkylator, such as Mitomycin, and Procarbazine, Dacarbazine and Altretamine; DNA strand breaking agents include Bleomycin; DNA topoisomerase II inhibitors include the following: Intercalators, such as Amsacrine, Dactinomycin, Daunorubicin, Doxorubicin, Idarubicin, and Mitoxantrone; nonintercalators, such as Etoposide and Teniposide. The DNA minor groove binder is Plicamycin.


The Antimetabolites interfere with the production of nucleic acids by one or the other of two major mechanisms. Some of the drugs inhibit production of the deoxyribonucleoside triphosphates that are the immediate precursors for DNA synthesis, thus inhibiting DNA replication. Some of the compounds are sufficiently like purines or pyrimidines to be able to substitute for them in the anobolic nucleotide pathways. These analogs can then be substituted into the DNA and RNA instead of their normal counterparts. The Antimetabolites useful herein include: folate antagonists such as Methotrexate and trimetrexate pyrimidine antagonists, such as Fluorouracil, Fluorodeoxyuridine, CB3717, Azacytidine, Cytarabine, and Floxuridine purine antagonists include Mercaptopurine, 6-Thioguanine, Fludarabine, Pentostatin; sugar modified analogs include Cyctrabine, Fludarabine; ribonucleotide reductase inhibitors include Hydroxyurea.


Tubulin Interactive agents act by binding to specific sites on Tubulin, a protein that polymerizes to form cellular microtubules. Microtubules are critical cell structure units. When the interactive agents bind on the protein, the cell cannot form microtubules Tubulin Interactive agents include Vincristine and Vinblastine, both alkaloids and Paclitaxel.


Hormonal agents are also useful in the treatment of cancers and tumors. They are used in hormonally susceptible tumors and are usually derived from natural sources. These include: estrogens, conjugated estrogens and Ethinyl Estradiol and Diethylstilbestrol, Chlorotrianisene and Idenestrol; progestins such as Hydroxyprogesterone caproate, Medroxyprogesterone, and Megestrol; androgens such as testosterone, testosterone propionate; fluoxymesterone, methyltestosterone; Adrenal corticosteroids are derived from natural adrenal cortisol or hydrocortisone. They are used because of their anti-inflammatory benefits as well as the ability of some to inhibit mitotic divisions and to halt DNA synthesis. These compounds include Prednisone, Dexamethasone, Methylprednisolone, and Prednisolone.


Leutinizing hormone releasing hormone agents or gonadotropin-releasing hormone antagonists are used primarily the treatment of prostate cancer. These include leuprolide acetate and goserelin acetate. They prevent the biosynthesis of steroids in the testes.


Antihormonal antigens include antiestrogenic agents such as Tamosifen, antiandrogen agents such as Flutamide; and antiadrenal agents such as Mitotane and Aminoglutethimide. Hydroxyurea appears to act primarily through inhibition of the enzyme ribonucleotide reductase. Asparaginase is an enzyme that converts asparagine to nonfunctional aspartic acid and thus blocks protein synthesis in the tumor.


While the foregoing represents some preferred embodiments of the present invention, other antimicrobial and chemotherapeutic agents and coating techniques may be utilized.


A preferred embodiment of a stent of the present invention is made of a shape-memory material such as nickel titanium (nitinol). A tracheal stent, in accordance with the present invention, has a substantially D shaped scaffolding to accommodate the trachea, which has stiff cartilaginous C rings that form the anterior and side walls of this organ while the posterior wall is elastic. The shape-memory material frame may be stamped into a variety of patterns such as that disclosed in German Pat. No. DE-199-06-956, herein incorporated in its entirety by reference.


The frame may be coated with a thin coating (preferably silicone, polyurethane or comparable material adaptable by one skilled in the art) to the extent sufficient to prevent the stent from becoming epithelialized and facilitating removal. In a preferred embodiment, the coating is coupled with the stent about the proximal and/or distal ends and is not anchored to the stent there between. The coating may be porous, but is not required to be. Rather it is preferable that the coating be sufficiently durable to remain functional when the stent is flexed, recaptured or deployed. Moreover, the material from which the coating is selected is limited only by the requirement that the coating allow for full and independent self-expansion even after being constrained and sterilized on the delivery system. It must also be noted that the stent may alternatively be polished. The polishing step facilitates removal of the stent and helps to prevent epithelialization. As a result the polished stent may be used with or without the above referenced coating. The polishing process comprises an electrical polishing process that produces a polished stent wall thickness to a range of about 175 μm-220 μm, and preferably 205 μm, which is about 40% thinner and reduces radial force by 50% with respect to conventional stents. Additionally, the present polishing process provides for a proportional decrease of radial force radial force as wall thickness decreases.


The ends of the stent may be configured to have flanges to prevent migration. In an embodiment having flanges, the ends of each flange are tapered slightly back into the airway thus preventing the ends of the stent from irritating the airway wall. However, providing a stent that is capable of retaining its axial working length while undergoing radial compression also prevents migration. As a result, the stent is more flexible and comfortable since the diameter of the stent can be increased without shortening the stent. Moreover, the resiliency of the stent can be varied over the length and/or cross-section of the stent. Moreover, suture holes are provided so that suture may be used as an anchor to facilitate removal of the stent. To this end, the stent may be deployed with or without suture already coupled with the stent.


An exemplary bronchial stent, in accordance with the present invention, will have similar features as the tracheal stent except that it is substantially tubular in shape. Though the stents are not equivalent, in view of the present disclosure, one of ordinary skill in the art would be able to make the necessary modifications to provide an exemplary tracheal stent.


It should also be kept in mind that though the present discussion has principally focused on airway stents, the device and methods of the present invention are useful in a wide variety of locations within a patient, for example but not limited to the esophagus, trachea, colon, billiary tract, urinary tract and vascular system. They are particularly advantageous for reliably delivering suitable therapeutic agents. In fact, a stent in accordance with the present invention can be configured to serve as a chemotherapeutic and/or antimicrobial agent targeted delivery system suitable for use in a variety of other lumens throughout the anatomy of a patient.


An advantage of the manufacturing process for stents in accordance with the present invention is the ability to modify the relative hardness/softness of regions of the stent. In particular any given region of the stent can differ from other regions of the stent to provide additional patient comfort and resistance to radial forces. This is preferably achieved by changing the relative geometries of the stent scaffolding interstices. In particular, by changing the height and/or width of the loop interstices, relative hardness/softness and radial strength can be adjusted. Moreover, the ability of the stent to flex and resist torsional strain can be enhanced by these interstice adjustments. It should be noted that the present inventors have discovered that all of the above-enumerated features may be incorporated in a bronchial Y-stent. Moreover, unlike conventional Y-stents that are either rubber and/or comprise a modular configuration of parts, a Y-stent in accordance with the present invention is a unitary self-expanding memory metal construction.


Turning now to the figures where like numerals refer to like components, of exemplary appliances in accordance with the present invention, the medical appliances are referred to generally with reference numerals 110, 210 and 310. Referring particularly to FIGS. 1-5, a medical appliance 110, is provided that has a unitary memory metal construction. The appliance 110 itself, defines a lumen there through which extends the longitudinal distance of the appliance 110 from the proximal end 112 to the distal end 114. The appliance 110 is preferably a luminal stent having a middle section 113 of a defined diameter that is dimensionally narrower than the defined diameter at the proximal end 112 and/or the distal end 114. FIG. 4 shows a luminal stent in accordance with the present invention that has a flared distal end 114 but not a flared proximal end 112. The appliance can be configured to have the opposite ends flared or no flared ends at all. The luminal stent also is formed of memory metal and preferably has unique geometrical interstices 116 laser etched therein. However, other conventional ways of forming interstices in unitary stents, though not equivalent, are contemplated, may be employed and would be within the skill set of one in the art.


It cannot be overemphasized, however, that this does not mean the knowledge that changes in the geometry of interstices 116 affect stent functionality is currently known in the art. To the contrary, the present inventors discovered the interrelation between interstice geometry, width, length and relative resistance to torsional stress and radial force. In fact, it can be said that the luminal stent 110 has circumferential bands extending perpendicularly with respect to the luminal device's longitudinal axis. A connector 118 connects these bands to one another; the connector 118 is an additional means for adjusting stent functionality. In particular, the connector 118 defines a substantially U shaped member.


As can be seen in FIGS. 2, 5 and 14, for example, the plurality of expandable circumferential bands of the appliance 110 are formed of struts having interconnected ends, which define a series of alternating peaks and valleys. The peaks and valleys of adjacent circumferential bands are in-phase except for at least one out-of-phase pair of circumferential bands. In FIG. 2, three pairs of circumferential bands are illustrated as being out-of-phase, and in FIGS. 5 and 14, one pair of circumferential bands is illustrated as being out-of-phase. A plurality of the flexible connectors 118 extend between each pair of the circumferential bands, and at least one set of the flexible connectors extends between and connects at least one pair of peaks or one pair of valleys of the out-of-phase pair of circumferential bands. The distal end 114 of the cylindrical member is defined by a circumferential band connected to flexible connectors 118 that extend only in the proximal direction, and the proximal end 112 of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the distal direction.


In a standard orientation, the substantially U-shape comprises preferably two leg members and a crossing member that connects with and extends perpendicularly at a 90° angles with respect to the leg members. The present inventors discovered that if you modify the length of the crossing member and/or the leg members and/or the angle at which the crossing member and the leg members intersect, the relative hardness/softness of the stent could be modified. The angles can be modified at varying acute angles short of 90°. The incremental changes correspondingly change certain characteristics of the stent. As a result, different regions of the luminal stent 110 can be given different rigidities to improve patient comfort and to facilitate luminal patency. Moreover, various anatomical lumens may need different degrees of stent rigidity. As a result, stents in accordance with the present invention can be manufactured to exacting specifications to contour properly to various lumens in a patient's anatomy, which may need varying levels of structural support from the medical appliance.


Referring now to FIGS. 14 and 15, luminal stent 110 is shown having substantially U shaped connectors 118 having a crossing member 119a and at least two leg members 119b-c respectively. The present inventors discovered that if you increase/decrease the length of leg members 119b and/or 119c, increase/decrease the length of crossing member 119a, and/or vary the angle at which crossing member 119a and leg members 119b-c intersect, you affect the functionality of the stent. In particular, the shorter the length of leg members 119a-b the less flexibility available in that portion of the stent. Taking particular note of FIG. 15, by way of example only, if you want to decrease the amount of torsional flexibility of the luminal stent 110, you would have to modify the desired portion of the stent to resemble 118f. However, if you want a stiffer appliance 110, you would have a configuration analogous to that of 118a.


In a preferred embodiment, the modification of interstice geometries' and manipulation of the U shaped connection member to achieve variable stent functionality is provided. The rigidity of the stent scaffolding or interstice matrix along with the torsionality of the stent itself is principally a function of these modifications. In an exemplary embodiment, the stents relative flexibility can be rated soft, medium or hard based on the degree of flex and torsionality. The less torsionality and flex in the stent the harder the stent is rated.


An exemplary stent in accordance with the present invention with relatively great torsionality and radial flexibility would be rated soft. An exemplary soft rated stent comprises distance between U shaped connectors of about 4.5 μm in the compressed state (i.e., contracted in the 3 mm tube subject to laser etching). Moreover, the length of the crossing member is preferably about 1.0 μm. The lengths of the leg members are preferably about 1.5 μm in length. Additionally the leg members may further comprise feet that attached to the remainder of the stent scaffolding. The feet can be adjusted from a standard length of about 0.25 μm to further adjust the characteristics of the stent. There is additionally a substantially rectangular member incorporated in the U shaped connector with similar capacity for variability. The variability factors and results of modifying the dimensions of the substantially rectangular members are similar to those evinced by leg length dimensional modifications.


By way of example, but not to be construed in any way as limiting, the softness index or relative flexibility can be increase by increasing the various lengths discussed above. For example, by increasing the length of the legs and crossing members of the U shaped connector, flexibility increases. However, with respect to the distance between U shaped members and distance between interstices in a preferred stent embodiment, there is an inverse correlation between length and softness. This relative softness/hardness indexing as a corollary of interstice dimensions is a novel aspect of preferred embodiment of the present invention. As a practical rule of thumb, longer leg lengths coupled with acute angles provide for greater flexibility. Conversely, shorter leg lengths and more obtuse angles provide more rigidity. By way of non-limiting example, a U shaped connector with short legs deviating from the crossing member at angles greater than 90°, will be extremely rigid and resistant to torsional strain as compared to a U shaped connector with longer legs diverging from the crossing member at angles less than 90°.


In addition to the length and spacing differences, the interstices themselves may define various shapes that by their very nature afford novel functionality to the stent. The changes of functionality, however, are more a function of the dimensional differences of the various shapes rather than a function of the shapes themselves. Therefore, it is important to keep in mind that the dimensional differences discussed in the previous paragraph are determinative of the functionality accorded the stent by the varying interstice geometries. It is for this reason that one of ordinary skill in the art, after being apprised of the present invention, would be able to conceive of a number of interstice geometries to satisfy certain functionality criteria by keeping certain dimensional parameters constant.


Referring now to FIG. 16, an exemplary Y-shaped stent 410 is shown that exemplifies the characteristics of luminal stents 110, 210 and 310. The Y-shaped stent also incorporates the advantages discussed above, including but not limited to, interstice geometrical advantages, polishing advantages, inward extending termini, suture apertures, antimicrobial and chemotherapeutic agent delivery, coating, etc.


In a preferred embodiment of a luminal stent in accordance with the present invention as shown in FIGS. 1-5, the proximal end 112 and the distal end 114 defines a plurality of apertures 120 for receiving suture. The luminal stent 110 may be deployed with or without suture engaged to facilitate the stent removal process.


As discussed above, a preferred luminal stent 110 further comprises a coating (not shown), which preferably extends the substantially the entire distance of the luminal stent 110. In particular, in a preferred embodiment the luminal stent is coated from about the proximal end 112 to the distal end 114, inclusive of suture apertures 120. Moreover, it is preferable that the coating is coupled with the luminal stent 110 about the proximal end 112 and distal end 114. The coating may be coupled to the luminal stent 110 by any number of adhesion systems available in the art. The principal requirement is that adhesive sufficiently couple the coating with luminal stent 110 so as to withstand the pressures of stent deployment, expansion, flexing and removal.


As an alternative, and in other embodiments in addition to, the coating an exemplary luminal stent 110 is electropolished to remove rough edges and to create a thinner more resilient appliance. In particular, the electrical polishing process produces a polished luminal stent wall thickness in the optimal range of about 175 μm-220 μm, and preferably 205 μm, which is about 40% thinner and reduces radial force by 50% with respect to conventional stents. Conventional stent polishing methods comprise a fluid abrasive media extruded through an apparatus in abrading contact with inner and outer surfaces and circumferential openings of a stent. As a result, conventional stent polishing methods are incapable of polishing stents to an optimal thickness that allows the stent to demonstrate characteristics of a covered stent in accordance with the present invention, namely, epithelialization retardation, enhanced removability, etc. As shown in Table 1, a polished stent in accordance with the present invention demonstrates desirable stent wall thickness, which is not achievable with shaping or staining processes. Moreover, standard polishing processing cannot achieve the desired stent wall thickness without compromising the integrity of the memory metal alloy and its shape memory characteristics.












TABLE 1






Wall Thickness
Fmax
Standard Deviation


Condition
(μm)
(Mean value)(mN)
(mN)


















Shaped
250
2733
296


Stained
233
1848
165


Polished
205
1518
53










The reduced radial force extends the useful life of the luminal stent 110 while also reducing significantly the pressure the stent exerts on the luminal tissue. It has been determined that as stent wall thickness decreases radial force decreases as well. The optimal range is an important discovery since it allows for the design of a luminal stent 110 that achieves optimal stent migration prevention while exerting minimal pressure on the surrounding luminal tissue.


The radial strength of the stent is defined as the change of the diameter of the stent as a function of applied surrounding pressure once the stent is deployed. The greater the radial strength of the stent, the more the appliance will resist deformation as a result of the forces imposed on the stent by the lumen. Radial strength of stents can generally be tested by conventional methods known in the art, such as DH Kim et al., Korean J. Radiology, June 2001; 2:75-79.


Luminal stents 210 and 310 in accordance with the present invention are shown in FIGS. 6-13 showing alternative interstice geometries. Not shown are a wide variety of interstice geometries that are also acceptable alternatives to the preferred, V, W, Z, S and X geometries claimed herein. Moreover, FIGS. 9-13 shows luminal stent 310 that has a substantially flat side 322 that extends longitudinally between proximal end 312 and distal end 314. As pointed out above, though stents 210 and 310 are shown with flared proximal ends 212 & 312 and distal ends 214 & 314, respectively, flared ends are not necessary. It should also be pointed out with respect to the respective ends of luminal stents 110, 210 and 310; proximal 112, 212 & 312 and distal ends 114, 214 & 314 preferably orient inward towards its lumen. In particular, it is preferable that suture apertures 120, 220 & 320 extend away from the lumen of the tissue of the patient and toward one another.


The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative, and not restrictive. The scope of the invention is, therefore, indicated by the appended claims, rather than by the foregoing description. All changes, which come within the meaning and range of equivalency of the claims, are to be embraced within their scope.

Claims
  • 1. A medical appliance for placement within and removal from a portion of the anatomy of a patient, the appliance comprising: a scaffolding, the scaffolding configured to define a substantially cylindrical member having a distal end and a proximal end and extending longitudinally there between, forming a lumen there through, such that when pressure is exerted along varying points of the longitudinal extension of the appliance, the appliance does not undesirably foreshorten or elongate, said scaffolding comprising:a plurality of expandable circumferential bands formed of struts having interconnected ends defining a series of alternating peaks and valleys, said peaks and valleys of adjacent circumferential bands being in-phase except for at least one out-of-phase pair of circumferential bands, anda plurality of flexible connectors extending between each pair of the circumferential bands, wherein at least one set of the flexible connectors extends between and connects at least one pair of peaks or one pair of valleys of the out-of-phase pair of circumferential bands, wherein,each of the plurality of connectors are spaced apart from one another by at least one pair of peaks and one pair of valleys of adjacent circumferential bands, and further whereinthe distal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the proximal direction, and the proximal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the distal direction.
  • 2. The medical appliance of claim 1, wherein the medical appliance comprises at least three circumferential bands and a plurality of flexible connectors extending therebetween, and wherein a pair of the flexible connectors extending between adjacent circumferential rows are in axial alignment with one another.
  • 3. A medical appliance for placement within and removal from a portion of the anatomy of a patient, the appliance comprising: a scaffolding, the scaffolding configured to define a substantially cylindrical member having a distal end and a proximal end and extending longitudinally there between, forming a lumen there through, such that when pressure is exerted along varying points of the longitudinal extension of the appliance, the appliance does not undesirably foreshorten or elongate, wherein along the longitudinal extension of the appliance, the scaffolding forms geometrical patterns, said scaffolding comprising:a plurality of expandable circumferential bands formed of struts having interconnected ends defining a series of alternating peaks and valleys, said peaks and valleys of adjacent circumferential bands being in-phase except for at least one out-of-phase pair of circumferential bands, anda plurality of flexible connectors extending between each pair of the circumferential bands, wherein at least one set of the flexible connectors extends between and connects at least one pair of peaks or one pair of valleys of the out-of-phase pair of circumferential bands,each of the flexible connectors including a substantially U-shaped connector member coupled with portions of the geometrical patterns, the U-shaped connector comprising a crossing member and a plurality of leg members extending from the crossing member, wherein the length of the leg members and the degree of the angle at which the legs extend from the crossing member determines the relative flexibility of the medical appliance, wherein,each of the plurality of connectors are spaced apart from one another by at least one pair of peaks and one pair of valleys of adjacent circumferential bands, and further whereinthe distal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the proximal direction, and the proximal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the distal direction.
  • 4. The medical appliance of claim 3, wherein the angle at which the leg members extend from the crossing member is greater than about 90°.
  • 5. The medical appliance of claim 4, wherein the medical appliance is relatively rigid.
  • 6. The medical appliance of claim 3, wherein the angle at which the leg members extend from the crossing member is about 90° or less.
  • 7. The medical appliance of claim 6, wherein the medical appliance is relatively flexible.
  • 8. A medical appliance for placement within and removal from a portion of the anatomy of a patient, the appliance comprising: a scaffolding, the scaffolding configured to define a substantially cylindrical member having a distal end and a proximal end and extending longitudinally there between, forming a lumen there through, such that when pressure is exerted along varying points of the longitudinal extension of the appliance, the appliance does not undesirably foreshorten or elongate, wherein the thickness of the scaffolding is about between 150 μm and 220 μm said scaffolding comprising:a plurality of expandable circumferential bands formed of struts having interconnected ends defining a series of alternating peaks and valleys, said peaks and valleys of adjacent circumferential bands being in-phase except for at least one out-of-phase pair of circumferential bands, anda plurality of flexible connectors extending between each pair of the circumferential bands, wherein at least one set of the flexible connectors extends between and connects at least one pair of peaks or one pair of valleys of the out-of-phase pair of circumferential bands, wherein,each of the plurality of connectors are spaced apart from one another by at least one pair of peaks and one pair of valleys of adjacent circumferential bands, and further whereinthe distal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the proximal direction, and the proximal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the distal direction.
  • 9. The medical appliance in accordance with claim 8, wherein the scaffolding thickness is about between 175 μm and 210 μm.
  • 10. The medical appliance of claim 9, wherein the thickness of the scaffolding is about between 195 μm and 205 μm.
  • 11. The medical appliance of claim 10, wherein the scaffolding thickness is about 205 μm.
  • 12. A method of treating a patient suffering from luminal irregularities, comprising the steps of: providing a medical appliance comprising a scaffolding, the scaffolding configured to define a substantially cylindrical member having a distal end and a proximal end and extending longitudinally there between, forming a lumen there through, such that when pressure is exerted along varying points of the longitudinal extension of the appliance, the appliance does not undesirably foreshorten or elongate, said scaffolding comprising:a plurality of expandable circumferential bands formed of struts having interconnected ends defining a series of alternating peaks and valleys, said peaks and valleys of adjacent circumferential bands being in-phase except for at least one out-of-phase pair of circumferential bands, anda plurality of flexible connectors extending between each pair of the circumferential bands, wherein at least one set of the flexible connectors extends between and connects at least one pair of peaks or one pair of valleys of the out-of-phase pair of circumferential bands, wherein each of the plurality of connectors are spaced apart from one another by at least one pair of peaks and one pair of valleys of adjacent circumferential bands, and further wherein the distal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the proximal direction, and the proximal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the distal direction;installing the medical appliance in a non-vascular lumen of the patient;activating the expansion of the medical appliance in the desired location; andremoving the medical appliance from the lumen of the patient.
  • 13. A medical appliance for placement within and removal from a portion of the anatomy of a patient, the appliance comprising: an electropolished scaffolding, the scaffolding configured to define a substantially cylindrical member having a distal end and a proximal end and extending longitudinally there between, forming a lumen there through, such that when pressure is exerted along varying points of the longitudinal extension of the appliance, the appliance does not undesirably foreshorten or elongate, said scaffolding comprising:a plurality of expandable circumferential bands formed of struts having interconnected ends defining a series of alternating peaks and valleys, said peaks and valleys of adjacent circumferential bands being in-phase except for at least one out-of-phase pair of circumferential bands, anda plurality of flexible connectors extending between each pair of the circumferential bands, wherein at least one set of the flexible connectors extends between and connects at least one pair of peaks or one pair of valleys of the out-of-phase pair of circumferential bands, wherein,each of the plurality of connectors are spaced apart from one another by at least one pair of peaks and one pair of valleys of adjacent circumferential bands, and further whereinthe distal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the proximal direction, and the proximal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the distal direction and,wherein the scaffolding is electropolished.
  • 14. The medical appliance of claim 13, wherein along the longitudinal extension of the appliance, the scaffolding forms geometrical patterns.
  • 15. The medical appliance of claim 14, wherein the dimensions of the scaffolding geometry determine torsionality of the medical appliance.
  • 16. The medical appliance of claim 14, further comprising a substantially U-shaped connector member coupled with portions of the geometrical patterns, the U-shaped connector comprising a crossing member and a plurality of leg members extending from the crossing member.
  • 17. The medical appliance of claim 16, wherein the substantially U-shaped connector further comprises a rectangular detent extending from a leg thereof.
  • 18. The medical appliance of claim 16, wherein the length of the leg members and the degree of the angle at which the legs extend from the crossing member determines the relative flexibility of the medical appliance.
  • 19. The medical appliance of claim 18, wherein the angle at which the leg members extend from the crossing member is greater than about 90°.
  • 20. The medical appliance of claim 19, wherein the medical appliance is relatively rigid.
  • 21. The medical appliance of claim 18, wherein the angle at which the leg members extend from the crossing member is about 90° or less.
  • 22. The medical appliance of claim 21, wherein the medical appliance is relatively flexible.
  • 23. The medical appliance of claim 14, wherein the geometrical patterns are substantially W-shaped.
  • 24. The medical appliance of claim 14, wherein the geometrical patterns are substantially V-shaped.
  • 25. The medical appliance of claim 14, wherein the geometrical patterns are substantially Z-shaped.
  • 26. The medical appliance of claim 14, wherein the geometrical patterns are substantially S-shaped.
  • 27. The medical appliance of claim 14, wherein the geometrical patterns are substantially X-shaped.
  • 28. The medical appliance of claim 13, wherein the scaffolding is formed of a memory capable alloy.
  • 29. The medical appliance of claim 28, wherein the memory capable alloy has antimicrobial properties.
  • 30. The medical appliance of claim 29, wherein the antimicrobial alloy is selected from the group consisting of group eleven metals.
  • 31. The medical appliance of claim 13, wherein near the distal and proximal ends of the scaffolding the medical appliance further comprise a plurality of flanges that define apertures there through.
  • 32. The medical appliance of claim 13, wherein the scaffolding further comprises an antimicrobial agent coupled therewith.
  • 33. The medical appliance of claim 32, wherein the antimicrobial agent is selected from the group consisting of tetracyclines, rifamycins, macrolides, penicillins, cephalosporins, p-lactam antibiotics, aminoglycosides, chloramphenicols, sulfonamides, glycopeptides, quinolones, fluidic acid, trimethoprim, metornidazole, clindamycin, mupirocin, polyenes, azoles, and beta-lactam inhibitors.
  • 34. The medical appliance of claim 13, wherein the scaffolding further comprises an antiseptic or disinfectant coupled therewith.
  • 35. The medical appliance of claim 34, wherein the antiseptic or disinfectant is selected from the group consisting of thymol, .alpha.-terpineol, methylisothiazolone, cetylpyridinium, chloroxylenol, hexachlorophene, cationic biguanides, methylene chloride, iodine and iodophores, triclosan, furan medical preparations, methenamine, aldehydes and alcohols.
  • 36. The medical appliance of claim 13, wherein the scaffolding may be made in its entirety or in part of an antimicrobial metal.
  • 37. The medical appliance of claim 13, wherein at least one surface of the scaffolding may have embedded, by ion beam assisted deposition, therein with atoms of an antimicrobial metal.
  • 38. The medical appliance of claim 13, wherein the scaffolding further comprises a chemotherapeutic agent coupled therewith.
  • 39. The medical appliance of claim 38, wherein the chemotherapeutic agent is selected from the group consisting of DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents, Hormonal agents and others such as Asparaginase or Hydroxyurea.
  • 40. The medical appliance of claim 39, wherein the DNA-Interactive Agents are selected from the group consisting of alkylating agents, the DNA strand-breakage agents, the intercalating topoisomerase II inhibitors, and the nonintercalating topoisomerase H inhibitors.
  • 41. The medical appliance of claim 40, wherein the alkylating agents are selected from the group consisting of Nitrogen mustards, aziridines, nitroso ureas, platinum complexes, bioreductive alkylator, DNA strand breaking agents, Intercalators and nonintercalators.
  • 42. The medical appliance of claim 39, wherein the Antimetabolites are selected from the group consisting of folate antagonists such as Methotrexate and trimetrexate; pyrimidine antagonists, such as Fluorouracil, Fluorodeoxyuridine, CB3717, Azacytidine, Cytarabine; Floxuridine purine antagonists include Mercaptopurine, 6-Thioguanine, Fludarabine, Pentostatin; sugar modified analogs include Cyctrabine, Fludarabine; and ribonucleotide reductase inhibitors include Hydroxyurea.
  • 43. The medical appliance of claim 13, wherein the scaffolding further comprises a hormonal agent coupled therewith.
  • 44. The medical appliance of claim 43, wherein the hormonal agent is selected from the group consisting of estrogens, conjugated estrogens; progestins; and androgens.
  • 45. The medical appliance of claim 13, wherein the scaffolding further comprises an anti-hormonal agent coupled therewith.
  • 46. The medical appliance of claim 45, wherein the anti-hormonal agent is selected from the group consisting of antiestrogenic, antiandrogen agents, and antiadrenal agents.
  • 47. The medical appliance of claim 46, wherein the thickness of the scaffolding is about between 150 μm and 220 μm.
  • 48. The medical appliance in accordance with claim 47, wherein the scaffolding thickness is about between 175 μm and 210 μm.
  • 49. The medical appliance of claim 48, wherein the thickness of the scaffolding is about between 195 μm and 205 μm.
  • 50. The medical appliance of claim 49, wherein the scaffolding thickness is about 205 μm.
  • 51. A method of treating a patient suffering from luminal irregularities, comprising the steps of: providing a medical appliance comprising an electropolished scaffolding, the scaffolding configured to define a substantially cylindrical member having a distal end and a proximal end and extending longitudinally there between, forming a lumen there through, such that when pressure is exerted along varying points of the longitudinal extension of the appliance, the appliance does not undesirably foreshorten or elongate, said scaffolding comprising:a plurality of expandable circumferential bands formed of struts having interconnected ends defining a series of alternating peaks and valleys, said peaks and valleys of adjacent circumferential bands being in-phase except for at least one out-of-phase pair of circumferential bands, anda plurality of flexible connectors extending between each pair of the circumferential bands, wherein at least one set of the flexible connectors extends between and connects at least one pair of peaks or one pair of valleys of the out-of-phase pair of circumferential bands, wherein each of the plurality of connectors are spaced apart from one another by at least one pair of peaks and one pair of valleys of adjacent circumferential bands, and further wherein the distal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the proximal direction, and the proximal end of the cylindrical member is defined by a circumferential band connected to flexible connectors that extend only in the distal direction;installing the medical appliance in a preferred location of the anatomy of the patient; andactivating the expansion of the medical appliance in the desired location.
  • 52. The method of claim 51, wherein the preferred location is a non-vascular lumen.
  • 53. The method of claim 52, further comprising the step of removing the medical appliance from the anatomy of the patient.
  • 54. The method of claim 52, wherein the medical appliance further comprises anti-microbial agents coupled therewith.
  • 55. The method of claim 52, wherein the medical appliance further comprises chemotherapeutic agents coupled therewith.
Parent Case Info

This patent application claims the benefit of priority under 35 U.S.C. § 119 to U.S. Provisional Application Ser. No. 60/308,071, filed Jul. 26, 2001.

US Referenced Citations (402)
Number Name Date Kind
3818511 Goldberg et al. Jun 1974 A
4343048 Ross et al. Aug 1982 A
4441215 Kaster Apr 1984 A
4655771 Wallsten Apr 1987 A
4665906 Jervis May 1987 A
4680031 Alonso Jul 1987 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4743251 Barra May 1988 A
4800882 Gianturco Jan 1989 A
4820262 Finney Apr 1989 A
4820298 Leveen et al. Apr 1989 A
4856516 Hillstead Aug 1989 A
4886062 Wiktor Dec 1989 A
5032128 Alonso Jul 1991 A
5061275 Wallsten et al. Oct 1991 A
5064435 Porter Nov 1991 A
5067957 Jervis Nov 1991 A
5073694 Tessier et al. Dec 1991 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5190546 Jervis Mar 1993 A
5195984 Schatz Mar 1993 A
5229431 Pinchuk Jul 1993 A
5292331 Boneau Mar 1994 A
5345057 Muller Sep 1994 A
5354309 Schnepp-Pesch et al. Oct 1994 A
5356423 Tihon et al. Oct 1994 A
5383892 Cardon et al. Jan 1995 A
5383925 Schmitt Jan 1995 A
5421955 Lau et al. Jun 1995 A
5433723 Lindenberg et al. Jul 1995 A
5443498 Fontaine Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5480431 Frietag et al. Jan 1996 A
5514154 Lau et al. May 1996 A
5520697 Lindenberg et al. May 1996 A
5534287 Lukic Jul 1996 A
5540713 Schnepp-Pesch et al. Jul 1996 A
5562725 Schmitt et al. Oct 1996 A
5575818 Pinchuk Nov 1996 A
5591157 Hennings et al. Jan 1997 A
5591197 Orth et al. Jan 1997 A
5593442 Klein Jan 1997 A
5597378 Jervis Jan 1997 A
5601593 Freitag Feb 1997 A
5609629 Fearnot et al. Mar 1997 A
5618301 Hauenstein et al. Apr 1997 A
5628788 Pinchuk May 1997 A
5643312 Fischell et al. Jul 1997 A
5645559 Hachtman et al. Jul 1997 A
5662713 Andersen et al. Sep 1997 A
5667486 Mikulich et al. Sep 1997 A
5674241 Bley et al. Oct 1997 A
5681346 Orth et al. Oct 1997 A
5697971 Fischell et al. Dec 1997 A
5707386 Schnepp-Pesch et al. Jan 1998 A
5713949 Jayaraman Feb 1998 A
5716393 Lindenberg et al. Feb 1998 A
5725572 Lam et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5741333 Frid Apr 1998 A
5755776 Al-Saadon May 1998 A
5755781 Jayaraman May 1998 A
5759192 Saunders Jun 1998 A
5766238 Lau et al. Jun 1998 A
5776161 Globerman Jul 1998 A
5780807 Saunders Jul 1998 A
5807404 Richter Sep 1998 A
5814063 Freitag Sep 1998 A
5824042 Lombardi et al. Oct 1998 A
5827321 Roubin et al. Oct 1998 A
5833707 McIntyre et al. Nov 1998 A
5836966 St. Germain Nov 1998 A
5837313 Ding et al. Nov 1998 A
5843120 Israel et al. Dec 1998 A
5853419 Imran Dec 1998 A
5860998 Robinson et al. Jan 1999 A
5860999 Schnepp-Pesch et al. Jan 1999 A
5873904 Ragheb et al. Feb 1999 A
5876418 Hauenstein et al. Mar 1999 A
5876445 Andersen et al. Mar 1999 A
5876448 Thompson et al. Mar 1999 A
5876449 Starck et al. Mar 1999 A
5879370 Fischell et al. Mar 1999 A
5902475 Trozera et al. May 1999 A
5911732 Hojeibane Jun 1999 A
5922019 Hankh et al. Jul 1999 A
5922020 Klein et al. Jul 1999 A
5922393 Jayaraman Jul 1999 A
5931866 Frantzen Aug 1999 A
5935162 Dang Aug 1999 A
5938682 Hojeibane et al. Aug 1999 A
5968070 Bley et al. Oct 1999 A
5968091 Pinchuk et al. Oct 1999 A
5971950 Lopez et al. Oct 1999 A
5972018 Israel et al. Oct 1999 A
5980552 Pinchasik et al. Nov 1999 A
6017365 Von Oepen Jan 2000 A
6022371 Killion Feb 2000 A
6027527 Asano et al. Feb 2000 A
6033435 Penn et al. Mar 2000 A
6042597 Kveen et al. Mar 2000 A
6048361 Von Oepen Apr 2000 A
6051021 Frid Apr 2000 A
6053941 Lindenberg et al. Apr 2000 A
6056775 Borghi et al. May 2000 A
6059811 Pinchasik et al. May 2000 A
6096070 Ragheb et al. Aug 2000 A
6099560 Penn et al. Aug 2000 A
6106548 Roubin et al. Aug 2000 A
6120534 Ruiz Sep 2000 A
6131266 Saunders Oct 2000 A
6132461 Thompson Oct 2000 A
6136006 Johnson et al. Oct 2000 A
6136022 Nunez et al. Oct 2000 A
6146403 St. Germain Nov 2000 A
6146416 Andersen et al. Nov 2000 A
6156052 Richter et al. Dec 2000 A
6159238 Killion et al. Dec 2000 A
6159239 Greenhalgh Dec 2000 A
6171334 Cox Jan 2001 B1
6174329 Callol et al. Jan 2001 B1
6179867 Cox Jan 2001 B1
6183506 Penn et al. Feb 2001 B1
6190407 Ogle et al. Feb 2001 B1
6193744 Ehr et al. Feb 2001 B1
6203568 Lombardi et al. Mar 2001 B1
6206916 Furst Mar 2001 B1
6217608 Penn et al. Apr 2001 B1
6231598 Berry et al. May 2001 B1
6231599 Ley May 2001 B1
6241760 Jang Jun 2001 B1
6248058 Silverman et al. Jun 2001 B1
6251134 Alt et al. Jun 2001 B1
6258121 Yang et al. Jul 2001 B1
6270524 Kim Aug 2001 B1
6273910 Limon Aug 2001 B1
6283992 Hankh et al. Sep 2001 B1
6293964 Yadav Sep 2001 B1
6293966 Frantzen Sep 2001 B1
6293968 Taheri Sep 2001 B1
6306141 Jervis Oct 2001 B1
6312459 Huang et al. Nov 2001 B1
6315794 Richter Nov 2001 B1
6325821 Gaschino et al. Dec 2001 B1
6325825 Kula et al. Dec 2001 B1
6336938 Kavteladze et al. Jan 2002 B1
6348065 Brown et al. Feb 2002 B1
6352552 Levinson et al. Mar 2002 B1
6355063 Calcote Mar 2002 B1
6361557 Gittings et al. Mar 2002 B1
6375676 Cox Apr 2002 B1
6375677 Penn et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6395020 Ley et al. May 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6409754 Smith et al. Jun 2002 B1
6416538 Ley et al. Jul 2002 B1
6420378 Rubinfeld Jul 2002 B1
6423084 St. Germain Jul 2002 B1
6423091 Hojeibane Jul 2002 B1
6428570 Globerman Aug 2002 B1
6432133 Lau et al. Aug 2002 B1
6436133 Furst et al. Aug 2002 B1
6440162 Cox et al. Aug 2002 B1
6443982 Israel et al. Sep 2002 B1
6451049 Vallana et al. Sep 2002 B2
6461380 Cox Oct 2002 B1
6461381 Israel et al. Oct 2002 B2
6464720 Boatman et al. Oct 2002 B2
6464722 Israel et al. Oct 2002 B2
6471721 Dang Oct 2002 B1
6475234 Richter et al. Nov 2002 B1
6475236 Roubin et al. Nov 2002 B1
6478815 Alt Nov 2002 B1
6488703 Kveen et al. Dec 2002 B1
6508834 Pinchasik et al. Jan 2003 B1
6514285 Pinchasik Feb 2003 B1
6533805 Jervis Mar 2003 B1
6533810 Hankh et al. Mar 2003 B2
6540777 Stenzel Apr 2003 B2
6551351 Smith et al. Apr 2003 B2
6569194 Pelton May 2003 B1
6572646 Boylan et al. Jun 2003 B1
6589276 Pinchasik et al. Jul 2003 B2
6602285 Von Oepen et al. Aug 2003 B1
6613078 Barone Sep 2003 B1
6613079 Wolinsky et al. Sep 2003 B1
6613080 Lootz Sep 2003 B1
6613081 Kim et al. Sep 2003 B2
6616688 Von Oepen Sep 2003 B2
6616689 Ainsworth et al. Sep 2003 B1
6616690 Rolando et al. Sep 2003 B2
6620192 Jalisi Sep 2003 B1
6620193 Lau et al. Sep 2003 B1
6620201 Nadal et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6623520 Jalisi Sep 2003 B2
6629994 Gomez et al. Oct 2003 B2
6635084 Israel et al. Oct 2003 B2
6638293 Makower et al. Oct 2003 B1
6638300 Frantzen Oct 2003 B1
6638302 Curcio et al. Oct 2003 B1
6641607 Hossainy et al. Nov 2003 B1
6641608 Pulnev Nov 2003 B1
6641609 Globerman Nov 2003 B2
6641611 Jayaraman Nov 2003 B2
6645240 Yee Nov 2003 B2
6645242 Quinn Nov 2003 B1
6652572 Kugler et al. Nov 2003 B2
6652573 Von Oepen Nov 2003 B2
6652575 Wang Nov 2003 B2
6652579 Cox et al. Nov 2003 B1
6653426 Alvarado et al. Nov 2003 B2
6656201 Ferrera et al. Dec 2003 B2
6656214 Fogarty et al. Dec 2003 B1
6656216 Hossainy et al. Dec 2003 B1
6656217 Herzog, Jr. et al. Dec 2003 B1
6656220 Gomez et al. Dec 2003 B1
6656351 Boyle Dec 2003 B2
6660019 Richter et al. Dec 2003 B1
6660030 Shaolian et al. Dec 2003 B2
6660034 Mandrusov et al. Dec 2003 B1
6660827 Loomis et al. Dec 2003 B2
6663664 Pacetti Dec 2003 B1
6664335 Krishnan Dec 2003 B2
6666881 Richter et al. Dec 2003 B1
6666884 Webster Dec 2003 B1
6669721 Bose et al. Dec 2003 B1
6669722 Chen et al. Dec 2003 B2
6669723 Killion et al. Dec 2003 B2
6673102 Vonesh et al. Jan 2004 B1
6673103 Golds et al. Jan 2004 B1
6673104 Barry Jan 2004 B2
6673105 Chen Jan 2004 B1
6673106 Mitelberg et al. Jan 2004 B2
6673107 Brandt et al. Jan 2004 B1
6673154 Pacetti et al. Jan 2004 B1
6676697 Richter Jan 2004 B1
6679910 Granada Jan 2004 B1
6679911 Burgermeister Jan 2004 B2
6682554 Oepen et al. Jan 2004 B2
6685736 White et al. Feb 2004 B1
6685745 Reever Feb 2004 B2
6689158 White et al. Feb 2004 B1
6689162 Thompson Feb 2004 B1
6692483 Vardi et al. Feb 2004 B2
6692521 Pinchasik Feb 2004 B2
6692522 Richter Feb 2004 B1
6695833 Frantzen Feb 2004 B1
6695876 Marotta et al. Feb 2004 B1
6699276 Sogard et al. Mar 2004 B2
6699278 Fischell et al. Mar 2004 B2
6706061 Fischell et al. Mar 2004 B1
6706062 Vardi et al. Mar 2004 B2
6709440 Callol et al. Mar 2004 B2
6709451 Noble et al. Mar 2004 B1
6709453 Pinchasik et al. Mar 2004 B2
6709454 Cox et al. Mar 2004 B1
6712843 Elliott Mar 2004 B2
6712844 Pacetti Mar 2004 B2
6712846 Kraus et al. Mar 2004 B1
6716240 Fischell et al. Apr 2004 B2
6719782 Chuter Apr 2004 B1
6719991 Darouiche et al. Apr 2004 B2
6723118 Ballou et al. Apr 2004 B1
6723119 Pinchasik et al. Apr 2004 B2
6723120 Yan Apr 2004 B2
6723121 Zhong Apr 2004 B1
6723373 Narayanan et al. Apr 2004 B1
6730064 Ragheb et al. May 2004 B2
6730116 Wolinsky et al. May 2004 B1
6730117 Tseng et al. May 2004 B1
6730120 Berg et al. May 2004 B2
6733523 Shaolian et al. May 2004 B2
6733524 Tseng et al. May 2004 B2
6736838 Richter May 2004 B1
6736843 Fariabi May 2004 B1
6736844 Glatt et al. May 2004 B1
6740113 Vrba May 2004 B2
6740114 Burgermeister May 2004 B2
6740115 Lombardi et al. May 2004 B2
6743252 Bates et al. Jun 2004 B1
6746475 Rivelli, Jr. Jun 2004 B1
6746476 Hojeibane Jun 2004 B1
6746477 Moore Jun 2004 B2
6746479 Ehr et al. Jun 2004 B2
6746482 Ung-Chhun Jun 2004 B2
6749629 Hong et al. Jun 2004 B1
6752826 Holloway et al. Jun 2004 B2
6752829 Kocur et al. Jun 2004 B2
6753071 Pacetti Jun 2004 B1
6755856 Fierens et al. Jun 2004 B2
6756007 Pletzer et al. Jun 2004 B2
6758858 McCrea et al. Jul 2004 B2
6758859 Dang et al. Jul 2004 B1
6758860 Penn et al. Jul 2004 B1
6761731 Majercak Jul 2004 B2
6764505 Hossainy et al. Jul 2004 B1
6764506 Roubin et al. Jul 2004 B2
6764507 Shanley et al. Jul 2004 B2
6764519 Whitmore, III Jul 2004 B2
6770086 Girton Aug 2004 B1
6770088 Jang Aug 2004 B1
6770089 Hong et al. Aug 2004 B1
6770091 Richter et al. Aug 2004 B2
6773445 Finlay et al. Aug 2004 B2
6774157 DelMain Aug 2004 B2
6774278 Ragheb et al. Aug 2004 B1
6776022 Kula et al. Aug 2004 B2
6776792 Yan et al. Aug 2004 B1
6776793 Brown et al. Aug 2004 B2
6776794 Hong et al. Aug 2004 B1
6776795 Pelton Aug 2004 B2
6776796 Falotico et al. Aug 2004 B2
6786929 Gambale et al. Sep 2004 B2
6790222 Kugler et al. Sep 2004 B2
6790227 Burgermeister Sep 2004 B2
6790228 Hossainy et al. Sep 2004 B2
6796997 Penn et al. Sep 2004 B1
6797217 McCrea et al. Sep 2004 B2
6800089 Wang Oct 2004 B1
6802859 Pazienza et al. Oct 2004 B1
6805702 Chen et al. Oct 2004 B1
6805703 McMorrow Oct 2004 B2
6805704 Hoyns Oct 2004 B1
6805705 Hong et al. Oct 2004 B2
6805706 Solovay et al. Oct 2004 B2
6805707 Hong et al. Oct 2004 B1
6805709 Schaldach et al. Oct 2004 B1
6805898 Wu et al. Oct 2004 B1
6808533 Goodwin et al. Oct 2004 B1
6814749 Cox et al. Nov 2004 B2
6818013 Mitelberg et al. Nov 2004 B2
6818014 Brown et al. Nov 2004 B2
6818015 Hankh et al. Nov 2004 B2
6818247 Chen et al. Nov 2004 B1
6821291 Bolea et al. Nov 2004 B2
6821292 Pazienza et al. Nov 2004 B2
6821293 Pinchasik Nov 2004 B2
6830638 Boylan et al. Dec 2004 B2
6833004 Ishii et al. Dec 2004 B2
6843802 Villalobos et al. Jan 2005 B1
6849086 Cragg Feb 2005 B2
6852124 Cox et al. Feb 2005 B2
6858037 Penn et al. Feb 2005 B2
6860898 Stack et al. Mar 2005 B2
6860900 Clerc et al. Mar 2005 B2
6863684 Kim et al. Mar 2005 B2
6866805 Hong et al. Mar 2005 B2
6875227 Yoon Apr 2005 B2
6878162 Bales et al. Apr 2005 B2
6881221 Golds Apr 2005 B2
6881222 White et al. Apr 2005 B2
6881223 Penn et al. Apr 2005 B2
6887264 Penn et al. May 2005 B2
6896696 Doran et al. May 2005 B2
6896697 Yip et al. May 2005 B1
6896698 Rolando et al. May 2005 B2
6899729 Cox et al. May 2005 B1
6908624 Hossainy et al. Jun 2005 B2
6911041 Zschecg Jun 2005 B1
6916336 Patel et al. Jul 2005 B2
6920677 Dolan et al. Jul 2005 B2
6955723 Pacetti et al. Oct 2005 B2
6979348 Sundar Dec 2005 B2
6997946 Girton et al. Feb 2006 B2
7004966 Edwin et al. Feb 2006 B2
20010000043 Israel et al. Mar 2001 A1
20010005793 Brenneman Jun 2001 A1
20010016767 Wilson et al. Aug 2001 A1
20010016768 Wilson et al. Aug 2001 A1
20010027339 Boatman et al. Oct 2001 A1
20010037138 Wilson et al. Nov 2001 A1
20020002396 Fulkerson Jan 2002 A1
20020002399 Huxel et al. Jan 2002 A1
20020042650 Vardi et al. Apr 2002 A1
20020045933 Jang Apr 2002 A1
20020111672 Kim et al. Aug 2002 A1
20020156524 Ehr et al. Oct 2002 A1
20020183831 Rolando et al. Dec 2002 A1
20020183832 Penn et al. Dec 2002 A1
20020193866 Saunders Dec 2002 A1
20020198593 Gomez et al. Dec 2002 A1
20030004567 Boyle et al. Jan 2003 A1
20030028240 Nolting et al. Feb 2003 A1
20030036793 Richter et al. Feb 2003 A1
20030045925 Jayaraman Mar 2003 A1
20030050690 Kveen et al. Mar 2003 A1
20030077310 Pathak et al. Apr 2003 A1
20030083734 Friedrich et al. May 2003 A1
20030105511 Welsh et al. Jun 2003 A1
20030105513 Moriuchi et al. Jun 2003 A1
20030114919 McQuiston et al. Jun 2003 A1
20030125799 Limon Jul 2003 A1
20030139796 Sequin et al. Jul 2003 A1
20030139803 Sequin et al. Jul 2003 A1
20030144726 Majercak et al. Jul 2003 A1
20030144731 Wolinsky et al. Jul 2003 A1
20030149469 Wolinsky et al. Aug 2003 A1
20030158596 Ikeuchi et al. Aug 2003 A1
Foreign Referenced Citations (40)
Number Date Country
2356911 Jul 2000 CA
299 04 817 Jul 1999 DE
199 06 956 Aug 2000 DE
199 06 956 A 1 Aug 2000 DE
199 37 638 A 1 May 2001 DE
0 183 372 Oct 1984 EP
0 350 302 Jan 1990 EP
0 378 151 Jul 1990 EP
0 540 290 Oct 1991 EP
0 540 290 May 1993 EP
0 621 015 Oct 1994 EP
0 797 963 Jan 1997 EP
0 792 627 Mar 1997 EP
0 945 107 Jan 1999 EP
1 088 528 Apr 2001 EP
1 093 771 Apr 2001 EP
1 208 814 Sep 2001 EP
1 151 730 Nov 2001 EP
1 197 188 Apr 2002 EP
1 290 984 Dec 2003 EP
2 758 253 Jul 1998 FR
2002-102251 Apr 2002 JP
2002-345971 Dec 2002 JP
WO 9113384 Sep 1991 WO
WO 9211824 Jul 1992 WO
WO 9322986 Nov 1993 WO
WO 9404096 Mar 1994 WO
WO 9421196 Sep 1994 WO
WO 9707751 Mar 1997 WO
WO 9710011 Mar 1997 WO
WO 9819628 May 1998 WO
WO 9902105 Jan 1999 WO
WO 9940876 Aug 1999 WO
WO 9962430 Dec 1999 WO
WO 0009041 Feb 2000 WO
WO 0044309 Aug 2000 WO
WO 0045742 Aug 2000 WO
WO 0176508 Oct 2001 WO
WO 0176508 Oct 2001 WO
WO 0219948 Mar 2002 WO
Related Publications (1)
Number Date Country
20030024534 A1 Feb 2003 US
Provisional Applications (1)
Number Date Country
60308071 Jul 2001 US